|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akiri G, Sabo E, Dafni H, Vadasz Z,
Kartvelishvily Y, Gan N, Kessler O, Cohen T, Resnick M, Neeman M
and Neufeld G: Lysyl oxidase-related protein-1 promotes tumor
fibrosis and tumor progression in vivo. Cancer Res. 63:1657–1666.
2003.PubMed/NCBI
|
|
3
|
Geach TJ and Dale L: Members of the lysyl
oxidase family are expressed during the development of the frog
Xenopus laevis. Differentiation. 73:414–424. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu X, Wang B and Xu Y: Expression of lysyl
oxidase in human osteosarcoma and its clinical significance: A
tumor suppressive role of LOX in human osteosarcoma cells. Int J
Oncol. 43:1578–1586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim YM, Kim EC and Kim Y: The human lysyl
oxidase-like 2 protein functions as an amine oxidase toward
collagen and elastin. Mol Biol Rep. 38:145–149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fong SF, Dietzsch E, Fong KS, Hollosi P,
Asuncion L, He Q, Parker MI and Csiszar K: Lysyl oxidase-like 2
expression is increased in colon and esophageal tumors and
associated with less differentiated colon tumors. Genes Chromosomes
Cancer. 46:644–655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Offenberg H, Brünner N, Mansilla F, Torben
Orntoft F and Birkenkamp-Demtroder K: TIMP-1 expression in human
colorectal cancer is associated with TGF-B1, LOXL2, INHBA1,
TNF-AIP6 and TIMP-2 transcript profiles. Mol Oncol. 2:233–240.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z,
Sun YM, Sun LC, Pan J, Sun LX, et al: Secreted LOXL2 is a novel
therapeutic target that promotes gastric cancer metastasis via the
Src/FAK pathway. Carcinogenesis. 30:1660–1669. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rückert F, Joensson P, Saeger HD,
Grützmann R and Pilarsky C: Functional analysis of LOXL2 in
pancreatic carcinoma. Int J Colorectal Dis. 25:303–311. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Erler JT and Giaccia AJ: Lysyl oxidase
mediates hypoxic control of metastasis. Cancer Res. 66:10238–10241.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peinado H, Moreno-Bueno G, Hardisson D,
Pérez-Gómez E, Santos V, Mendiola M, de Diego JI, Nistal M,
Quintanilla M, Portillo F and Cano A: Lysyl oxidase-like 2 as a new
poor prognosis marker of squamous cell carcinomas. Cancer Res.
68:4541–4550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barry-Hamilton V, Spangler R, Marshall D,
McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien
H, Wai C, et al: Allosteric inhibition of lysyl oxidase-like-2
impedes the development of a pathologic microenvironment. Nat Med.
16:1009–1017. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barker HE, Chang J, Cox TR, Lang G, Bird
D, Nicolau M, Evans HR, Gartland A and Erler JT: LOXL2-mediated
matrix remodeling in metastasis and mammary gland involution.
Cancer Res. 71:1561–1572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barker HE, Cox TR and Erler JT: The
rationale for targeting the LOX family in cancer. Nat Rev Cancer.
12:540–552. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peinado H, Del Carmen Iglesias-de la Cruz
M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A and
Portillo F: A molecular role for lysyl oxidase-like 2 enzyme in
snail regulation and tumor progression. EMBO J. 24:3446–3458. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamada S, Fuchs BC, Fujii T, Shimoyama Y,
Sugimoto H, Nomoto S, Takeda S, Tanabe KK, Kodera Y and Nakao A:
Epithelial-to-mesenchymal transition predicts prognosis of
pancreatic cancer. Surgery. 154:946–954. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamada S, Okumura N, Wei L, Fuchs BC,
Fujii T, Sugimoto H, Nomoto S, Takeda S, Tanabe KK and Kodera Y:
Epithelial to mesenchymal transition is associated with shorter
disease-free survival in hepatocellular carcinoma. Ann Surg Oncol.
21:3882–3890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu J, Huang S, Wu G, Huang C, Li X, Chen
Z, Zhao L and Zhao Y: Lysyl oxidase is predictive of unfavorable
outcomes and essential for regulation of vascular endothelial
growth factor in hepatocellular carcinoma. Dig Dis Sci.
60:3019–3031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang SS, Trackman PC and Kagan HM:
Reaction of aortic lysyl oxidase with beta-aminopropionitrile. J
Biol Chem. 258:4331–4338. 1983.PubMed/NCBI
|
|
21
|
Kirschmann DA, Seftor EA, Fong SF, Nieva
DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K and Hendrix MJ: A
molecular role for lysyl oxidase in breast cancer invasion. Cancer
Res. 62:4478–4483. 2002.PubMed/NCBI
|
|
22
|
Rahn DD, Good MM, Roshanravan SM, Shi H,
Schaffer JI, Singh RJ and Word RA: Effects of preoperative local
estrogen in postmenopausal women with prolapse: A randomized trial.
J Clin Endocrinol Metab. 99:3728–3736. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gunasekaran S, Weinstein P and Chvapil MJ:
Effect of topical beta APN application on evoked potential
conduction in rat sciatic nerve and spinal cord. Surg Neurol.
28:201–207. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
da Silva R, Uno M, Marie SK and Oba-Shinjo
SM: The lysyl oxidase inhibitor, beta-aminopropionitrile,
diminishes the metastatic colonization potential of circulating
breast cancer cells. PLoS One. 10:e01197812015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Payne SL, Hendrix MJ and Kirschmann DA:
Paradoxical roles for lysyl oxidases in cancer-a prospect. J Cell
Biochem. 101:1338–1354. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bouez C, Reynaud C, Noblesse E, Thépot A,
Gleyzal C, Kanitakis J, Perrier E, Damour O and Sommer P: The lysyl
oxidase LOX is absent in basal and squamous cell carcinomas and its
knockdown induces an invading phenotype in a skin equivalent model.
Clin Cancer Res. 12:1463–1469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaneda A, Wakazono K, Tsukamoto T,
Watanabe N, Yagi Y, Tatematsu M, Kaminishi M, Sugimura T and
Ushijima T: Lysyl oxidase is a tumor suppressor gene inactivated by
methylation and loss of heterozygosity in human gastric cancers.
Cancer Res. 64:6410–6415. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wong CC, Tse AP, Huang YP, Zhu YT, Chiu
DK, Lai RK, Au SL, Kai AK, Lee JM, Wei LL, et al: Lysyl
oxidase-like 2 is critical to tumor microenvironment and metastatic
niche formation in hepatocellular carcinoma. Hepatology.
60:1645–1658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zheng Y, Wang X, Wang H, Yan W, Zhang Q
and Chang X: Expression of the lysyl oxidase propeptide in
hepatocellular carcinoma and its clinical relevance. Oncol Rep.
31:1669–1676. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pez F, Dayan F, Durivault J, Kaniewski B,
Aimond G, Le Provost GS, Deux B, Clézardin P, Sommer P, Pouysségur
J and Reynaud C: The HIF-1-inducible lysyl oxidase activates HIF-1
via the Akt pathway in a positive regulation loop and synergizes
with HIF-1 in promoting tumor cell growth. Cancer Res.
71:1647–1657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bondareva A, Downey CM, Ayres F, Liu W,
Boyd SK, Hallgrimsson B and Jirik FR: The lysyl oxidase inhibitor,
beta-aminopropionitrile, diminishes the metastatic colonization
potential of circulating breast cancer cells. PLoS One.
4:e56202009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cano A, Santamaría PG and Moreno-Bueno G:
LOXL2 in epithelial cell plasticity and tumor progression. Future
Oncol. 8:1095–1108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Singh AB, Sharma A, Smith JJ, Krishnan M,
Chen X, Eschrich S, Washington MK, Yeatman TJ, Beauchamp RD and
Dhawan P: Claudin-1 up-regulates the repressor ZEB-1 to inhibit
E-cadherin expression in colon cancer cells. Gastroenterology.
141:2140–2153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen X, Wang Y, Xia H, Wang Q, Jiang X,
Lin Z, Ma Y, Yang Y and Hu M: Loss of E-cadherin promotes the
growth, invasion and drug resistance of colorectal cancer cells and
is associated with liver metastasis. Mol Biol Rep. 39:6707–6714.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Murai T, Yamada S, Fuchs BC, Fujii T,
Nakayama G, Sugimoto H, Koike M, Fujiwara M, Tanabe KK and Kodera
Y: Epithelial-to-mesenchymal transition predicts prognosis in
clinical gastric cancer. J Surg Oncol. 109:684–689. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mashita N, Yamada S, Nakayama G, Tanaka C,
Iwata N, Kanda M, Kobayashi D, Fujii T, Sugimoto H, Koike M, et al:
Epithelial to mesenchymal transition might be induced via CD44
isoform switching in colorectal cancer. J Surg Oncol. 110:745–751.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Moreno-Bueno G, Salvador F, Martín A,
Floristán A, Cuevas EP, Santos V, Montes A, Morales S, Castilla MA,
Rojo-Sebastián A, et al: Lysyl oxidase-like 2 (LOXL2), a new
regulator of cell polarity required for metastatic dissemination of
basal-like breast carcinomas. EMBO Mol Med. 3:528–544. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu L, Zhang Y, Zhu Y, Chong Q, Xiang Y and
Fu L: The effect of LOXL2 in hepatocellular carcinoma. Mol Med
Repl. 14:1923–1932. 2016. View Article : Google Scholar
|
